Recombinant human tissue kallikrein-1
Recombinant human tissue kallikrein-1, also known as DM199, is an experimental drug that acts on the kallikrein-kinin system and is developed for diabetes.[1][2][3][4]
References
[edit]- ^ Maneva-Radicheva, Lilia; Amatya, Christina; Parker, Camille; Ellefson, Jacob; Radichev, Ilian; Raghavan, Arvind; Charles, Matthew L.; Williams, Mark S.; Robbins, Mark S.; Savinov, Alexei Y. (26 September 2014). "Autoimmune Diabetes Is Suppressed by Treatment with Recombinant Human Tissue Kallikrein-1". PLOS ONE. 9 (9): e107213. Bibcode:2014PLoSO...9j7213M. doi:10.1371/journal.pone.0107213. PMC 4178025. PMID 25259810.
- ^ Charest-Morin, Xavier; Raghavan, Arvind; Charles, Matthew L.; Kolodka, Tadeusz; Bouthillier, Johanne; Jean, Mélissa; Robbins, Mark S.; Marceau, François (March 2015). "Pharmacological effects of recombinant human tissue kallikrein on bradykinin B 2 receptors". Pharmacology Research & Perspectives. 3 (2): e00119. doi:10.1002/prp2.119. PMC 4448978. PMID 26038695.
- ^ Kolodka, Tadeusz; Charles, Matthew L.; Raghavan, Arvind; Radichev, Ilian A.; Amatya, Christina; Ellefson, Jacob; Savinov, Alexei Y.; Nag, Abhijeet; Williams, Mark S.; Robbins, Mark S. (6 August 2014). "Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus". PLOS ONE. 9 (8): e103981. Bibcode:2014PLoSO...9j3981K. doi:10.1371/journal.pone.0103981. PMC 4123992. PMID 25100328.
- ^ Alexander-Curtis, Michelle; Pauls, Rick; Chao, Julie; Volpi, John J; Bath, Philip M; Verdoorn, Todd A. (January 2019). "Human tissue kallikrein in the treatment of acute ischemic stroke". Therapeutic Advances in Neurological Disorders. 12: 175628641882191. doi:10.1177/1756286418821918. PMC 6348491. PMID 30719079.